drugset / Trial / NCT01768676

Study Evaluating the Effects of Avanafil on Semen Parameters

NCT01768676 ↗

Phase 4 Completed 181 enrolled VIVUS LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether avanafil will affect different aspects of sperm production.

Timeline

Start
2012-12
Primary completion
2014-08
Completion
2014-08

Outcome

Met primary endpoint

registry analysis (non-inferiority or equivalence test); Avanafil vs Placebo; Risk Difference (RD) -12.93 (95% CI -21.56 to -4.29) NCT01768676 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Avanafil Small molecule 100 mg —

Indications